COAG (Hemab Therapeutics Holdings) Buyback Yield %: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COAG Hemab Therapeutics Holdings Inc COAG
12 GF Score
Price $41.19
! 1 Warning Sign
View Full Analysis

What is Hemab Therapeutics Holdings Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Hemab Therapeutics Holdings's current buyback yield was %.

Hemab Therapeutics Holdings Buyback Yield % Related Terms

Hemab Therapeutics Holdings Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Hemab Therapeutics Holdings's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemab Therapeutics Holdings Buyback Yield % Chart

Hemab Therapeutics Holdings Annual Data
Trend Dec24 Dec25
Buyback Yield %
- -

Hemab Therapeutics Holdings Quarterly Data
Mar25 Jun25 Mar26 Jun26
Buyback Yield % - - - -

COAG vs ADMA, VCEL, KLRA: Buyback Yield % Comparison

For the Biotechnology subindustry, Hemab Therapeutics Holdings's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemab Therapeutics Holdings Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemab Therapeutics Holdings's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Hemab Therapeutics Holdings's Buyback Yield % falls into.


COAG
12GF Score
Hemab Therapeutics Holdings Inc COAG
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemab Therapeutics Holdings Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Hemab Therapeutics Holdings's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-0 + 156.421) /
=N/A%

Hemab Therapeutics Holdings's annualized Buyback Yield for the quarter that ended in Jun. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 317.165) / 1715.4897093
=-18.49%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Hemab Therapeutics Holdings Business Description

Address 101 Main Street, Suite 1220, Cambridge, MA, USA, 02142
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
12GF Score

Get the complete analysis for COAG

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.19
Price